Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals: Promising Growth Trajectory with Strategic Focus and Pipeline Progress
- Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements
- Mirum Pharmaceuticals’ Earnings Call Highlights Growth and Future Prospects
- Mirum Pharmaceuticals price target raised to $65 from $63 at Morgan Stanley
- Mirum Pharmaceuticals price target raised to $55 from $50 at Baird